Journal of Neurology

, Volume 256, Issue 5, pp 711–716

Vestibular migraine: a critical review of treatment trials

Authors

    • Center for Balance, Dizziness, and VertigoLifeBridge Health Brain & Spine Institute
  • Braeme Glaun
    • LifeBridge Health Brain & Spine Institute
  • Susan Y. Quan
    • Department of Internal MedicineJohns Hopkins University School of Medicine
  • Tzipora Sofare
    • LifeBridge Health Brain & Spine Institute
Review

DOI: 10.1007/s00415-009-5050-5

Cite this article as:
Fotuhi, M., Glaun, B., Quan, S.Y. et al. J Neurol (2009) 256: 711. doi:10.1007/s00415-009-5050-5

Abstract

Vestibular migraine (VM), also known as migraine-associated vertigo, is a common cause of dizziness in adults. We performed a comprehensive literature search regarding treatment for VM or migraine-associated vertigo during the period of 1990–2008 and used, individually or in combination, the search terms VM, migraine-associated vertigo, migraine-associated dizziness, migrainous vertigo, migraine and vertigo, migraine and disequilibrium, and headache and vertigo. We found nine publications that address treatment strategies for VM. One small randomized clinical trial found some benefit from the use of zolmitriptan for abortive treatment of VM. The other eight observational studies showed marginal improvement with migraine prophylactic medications such as nortriptyline, verapamil, or metoprolol. Until more specific treatment options become available, patients with VM need to be managed with similar prophylactic and abortive strategies as those used for migraine in adults.

Keywords

Vestibular migraineMigraine-associated vertigoMigraineVertigoDizzinessHeadache

Copyright information

© Springer-Verlag 2009